| Features: oral antidiabetic agent, | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Metformin is a pleiotropic drug: attributed to its action on AMPK Metformin is a biguanide drug used primarily for type 2 diabetes. Mechanistically, it is best described as a bioenergetic modulator: partial inhibition of mitochondrial respiration can raise AMP/ADP, engage AMPK, and suppress mTORC1 signaling; systemically it reduces hepatic gluconeogenesis and can lower insulin/IGF-1 growth signaling. In oncology, observational studies suggested improved outcomes in some settings, but randomized trial data are mixed (e.g., large adjuvant breast cancer data did not show broad benefit overall). Long-term use can be associated with vitamin B12 deficiency, and prescribing requires attention to renal function due to rare lactic acidosis risk in predisposed states. Metformin directly(partially) inhibits Complex I of the electron transport chain (ETC) in mitochondria. This inhibition decreases mitochondrial ATP production and forces cells to rely more on glycolysis for energy. Cancer cells, especially those with high energy demands, may be particularly sensitive to a drop in ATP levels. The inhibition of Complex I also increases the AMP/ATP ratio, setting the stage for the activation of downstream energy stress pathways. AMPK activation results in the inhibition of the mammalian target of rapamycin (mTOR) pathway, a central regulator of protein synthesis and cellular growth. mTOR inhibition reduces cell proliferation and limits tissue growth, which can slow tumor progression. Metformin reduces circulating insulin levels, which in turn can decrease the activation of the insulin and insulin-like growth factor-1 (IGF-1) receptor pathways. ETC Inhibitors: Drugs that directly inhibit specific ETC complexes (e.g., Complex I inhibitors like metformin or phenformin) can increase electron leakage and ROS production.(dose- and context-dependent, and not consistent) -known as mild OXPHOS inhibitor(Complex I modulator)
Time-Scale Flag (TSF): P / R / G
|
| Source: |
| Type: protein |
| Manganese superoxide dismutase (MnSOD, also known as SOD2). SOD2 (Superoxide Dismutase 2) is a protein that is a member of the superoxide dismutase family of enzymes, which are involved in the detoxification of superoxide radicals. -MnSOD is localized in the mitochondria and plays a key role in detoxifying superoxide radicals, thereby limiting oxidative damage and maintaining mitochondrial integrity. • By modulating ROS levels, MnSOD influences cellular signaling pathways involved in proliferation, apoptosis, and metabolic adaptation—all of which are critical during tumorigenesis. Typically low SOD2 expression in cancers, with poor prognosis. -Increased MnSOD levels may help tumor cells manage the high levels of ROS resulting from rapid cell division and metabolic alterations, which can contribute to tumor progression. - Some prognostic studies associate high levels of MnSOD with resistance to apoptosis and poorer patient outcomes; however, findings are not entirely consistent across all studies. • Depending on the tumor type and the balance with other antioxidant systems, high MnSOD can be associated with either favorable or unfavorable clinical outcomes, reflecting its dual roles in cancer biology. |
| 5785- | MET, | Metformin improves healthspan and lifespan in mice |
| - | in-vivo, | Nor, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:11 Target#:935 State#:% Dir#:2
wNotes=0 sortOrder:rid,rpid